CATALENT PHARMA SOLUTIONS

Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product...

Under the terms of the agreement, Catalent will purchase the shares of SCTS, currently held by Bone Therapeutics, which owns and operates a...

The 23,000-square-foot facility, purchased from AB BioTechnologies, Inc. and its affiliate, includes a new Vanrx SA25 aseptic flexible filling...

T1367 is an autologous T-cell receptor-based cell therapy derived from T-knife’s proprietary humanized T-cell receptor (HuTCR) mouse platform...

Collaboration includes joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing...

Date: Tuesday, November 19, 2019 Duration: 1 hour The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the...

This arrangement significantly reduces Novavax’ operating costs and provides a cash payment at closing of approximately $18 million. This cost...

Elemental impurities can arise from a variety of sources, such as active pharmaceutical ingredients (APIs), excipients, manufacturing equipment...

Somerset, N.J. – December 15, 2016 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development...

Schedule to meet with Catalent at PDA Universe of Pre-Filled Syringes and Injection DevicesDate: October 8 - 9, 2018 Location: Loews Royal...